vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and SouthState Bank Corp (SSB). Click either name above to swap in a different company.
Elanco Animal Health Inc is the larger business by last-quarter revenue ($1.1B vs $661.7M, roughly 1.7× SouthState Bank Corp). SouthState Bank Corp runs the higher net margin — 34.1% vs -24.1%, a 58.3% gap on every dollar of revenue. Over the past eight quarters, SouthState Bank Corp's revenue compounded faster (37.4% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
SouthState Bank, based in Winter Haven, Florida, is an American bank and a subsidiary of SouthState Corporation, a bank holding company. As of May 26, 2025, the company had 371 branches in South Carolina, North Carolina, Georgia, Florida, Alabama, Virginia, Colorado and Texas.
ELAN vs SSB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $661.7M |
| Net Profit | $-276.0M | $225.8M |
| Gross Margin | 51.5% | — |
| Operating Margin | -22.6% | 15.1% |
| Net Margin | -24.1% | 34.1% |
| Revenue YoY | 12.2% | — |
| Net Profit YoY | -3350.0% | 153.5% |
| EPS (diluted) | $-0.55 | $2.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $661.7M | ||
| Q4 25 | $1.1B | $581.1M | ||
| Q3 25 | $1.1B | $599.7M | ||
| Q2 25 | $1.2B | $577.9M | ||
| Q1 25 | $1.2B | $544.5M | ||
| Q4 24 | $1.0B | $369.8M | ||
| Q3 24 | $1.0B | $351.5M | ||
| Q2 24 | $1.2B | $350.3M |
| Q1 26 | — | $225.8M | ||
| Q4 25 | $-276.0M | $247.7M | ||
| Q3 25 | $-34.0M | $246.6M | ||
| Q2 25 | $11.0M | $215.2M | ||
| Q1 25 | $67.0M | $89.1M | ||
| Q4 24 | $-8.0M | $144.2M | ||
| Q3 24 | $364.0M | $143.2M | ||
| Q2 24 | $-50.0M | $132.4M |
| Q1 26 | — | — | ||
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 58.2% | — |
| Q1 26 | — | 15.1% | ||
| Q4 25 | -22.6% | 54.3% | ||
| Q3 25 | -4.4% | 53.6% | ||
| Q2 25 | 2.0% | 48.8% | ||
| Q1 25 | 5.0% | 22.3% | ||
| Q4 24 | -5.0% | 50.7% | ||
| Q3 24 | 54.3% | 53.1% | ||
| Q2 24 | -2.7% | 49.3% |
| Q1 26 | — | 34.1% | ||
| Q4 25 | -24.1% | 42.6% | ||
| Q3 25 | -3.0% | 41.1% | ||
| Q2 25 | 0.9% | 37.2% | ||
| Q1 25 | 5.6% | 16.4% | ||
| Q4 24 | -0.8% | 39.0% | ||
| Q3 24 | 35.3% | 40.7% | ||
| Q2 24 | -4.2% | 37.8% |
| Q1 26 | — | $2.28 | ||
| Q4 25 | $-0.55 | $2.47 | ||
| Q3 25 | $-0.07 | $2.42 | ||
| Q2 25 | $0.02 | $2.11 | ||
| Q1 25 | $0.13 | $0.87 | ||
| Q4 24 | $-0.01 | $1.88 | ||
| Q3 24 | $0.73 | $1.86 | ||
| Q2 24 | $-0.10 | $1.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $2.9B |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $6.5B | $9.0B |
| Total Assets | $13.4B | $68.0B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.9B | ||
| Q4 25 | $545.0M | — | ||
| Q3 25 | $505.0M | — | ||
| Q2 25 | $539.0M | — | ||
| Q1 25 | $487.0M | — | ||
| Q4 24 | $468.0M | — | ||
| Q3 24 | $490.0M | — | ||
| Q2 24 | $416.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — |
| Q1 26 | — | $9.0B | ||
| Q4 25 | $6.5B | $9.1B | ||
| Q3 25 | $6.7B | $9.0B | ||
| Q2 25 | $6.8B | $8.8B | ||
| Q1 25 | $6.4B | $8.6B | ||
| Q4 24 | $6.1B | $5.9B | ||
| Q3 24 | $6.5B | $5.9B | ||
| Q2 24 | $5.9B | $5.7B |
| Q1 26 | — | $68.0B | ||
| Q4 25 | $13.4B | $67.2B | ||
| Q3 25 | $13.6B | $66.0B | ||
| Q2 25 | $13.7B | $65.9B | ||
| Q1 25 | $12.9B | $65.1B | ||
| Q4 24 | $12.6B | $46.4B | ||
| Q3 24 | $13.3B | $46.1B | ||
| Q2 24 | $13.8B | $45.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | — |
| Free Cash FlowOCF − Capex | $46.0M | — |
| FCF MarginFCF / Revenue | 4.0% | — |
| Capex IntensityCapex / Revenue | 5.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $108.0M | $232.1M | ||
| Q3 25 | $219.0M | $122.4M | ||
| Q2 25 | $237.0M | $72.6M | ||
| Q1 25 | $-4.0M | $-126.3M | ||
| Q4 24 | $177.0M | $354.3M | ||
| Q3 24 | $162.0M | $-246.8M | ||
| Q2 24 | $200.0M | $126.8M |
| Q1 26 | — | — | ||
| Q4 25 | $46.0M | $215.5M | ||
| Q3 25 | $127.0M | $101.7M | ||
| Q2 25 | $180.0M | $52.5M | ||
| Q1 25 | $-69.0M | $-139.1M | ||
| Q4 24 | $130.0M | $340.9M | ||
| Q3 24 | $120.0M | $-254.2M | ||
| Q2 24 | $166.0M | $117.3M |
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | 37.1% | ||
| Q3 25 | 11.2% | 17.0% | ||
| Q2 25 | 14.5% | 9.1% | ||
| Q1 25 | -5.8% | -25.5% | ||
| Q4 24 | 12.7% | 92.2% | ||
| Q3 24 | 11.7% | -72.3% | ||
| Q2 24 | 14.0% | 33.5% |
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | 2.9% | ||
| Q3 25 | 8.1% | 3.5% | ||
| Q2 25 | 4.6% | 3.5% | ||
| Q1 25 | 5.4% | 2.4% | ||
| Q4 24 | 4.6% | 3.6% | ||
| Q3 24 | 4.1% | 2.1% | ||
| Q2 24 | 2.9% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.94× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | 21.55× | 0.34× | ||
| Q1 25 | -0.06× | -1.42× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | 0.45× | -1.72× | ||
| Q2 24 | — | 0.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
